On June 10, 2024, GSK plc announced it is appealing a Delaware court ruling allowing plaintiff testimony in the Zantac (ranitidine) litigation, arguing the decision contradicts established legal standards. The company maintains there is no reliable evidence linking ranitidine to cancer risk, based on studies involving over 1 million patients.